BristolMyers Squibbs Novel Oral Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial

Efficacy endpoints including 75 and 90 reduction in the Psoriasis Area and Severity Index PASI 75 PASI 90 were achieved following 12 weeks of treatment with 3 mg daily of BMS986165 Data published in New England Journal of Med...